DDInter178 DDInter1715
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stages of the disease. It is usually presented mainly in patients with prostatic and breast cancer, as well as in cancer of lung, bladder and thyroid. There has been some cases of apparent tumor regression which has given it a potential tumoricidal effect.
Strontium chloride Sr-89 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carmustine
Strontium chloride Sr-89 {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Axicabtagene ciloleucel
Strontium chloride Sr-89 {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Carmustine
Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Axicabtagene ciloleucel
Strontium chloride Sr-89 may lead to a major life threatening interaction when taken with Clozapine